Literature DB >> 3719551

Cancer incidence, survival, and mortality for children younger than age 15 years.

J L Young, L G Ries, E Silverberg, J W Horm, R W Miller.   

Abstract

Incidence and survival data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program for the 10-year period 1973-1982 are presented. Childhood cancer incidence rates have remained relatively stable over the last decade. The overall incidence rate increased slightly from 124 to 127 per million children from 1973-1977 to 1978-1982 while rates for leukemias remained unchanged over this same time period at 38 per million for all races combined. Leukemias and lymphomas accounted for 44% of all cancers among white children and 33% among blacks. For all forms of cancer combined, the 5-year relative survival rate was 57% for both whites and blacks. The 5-year relative survival rate exceeded 80% for fibrosarcomas, retinoblastomas, Hodgkin's disease, and gonadal and germ cell tumors. Survival rates for children have shown improvement during the last decade, the most dramatic improvements occurring among patients with leukemia (15% 5-year relative survival in 1967-1973 versus 51% in 1973-1981), non-Hodgkin's lymphoma (24% versus 51%), and bone tumors (28% versus 48%).

Entities:  

Mesh:

Year:  1986        PMID: 3719551     DOI: 10.1002/1097-0142(19860715)58:2+<598::aid-cncr2820581332>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  60 in total

1.  Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.

Authors:  R G Weber; T Pietsch; D von Schweinitz; P Lichter
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Guidelines for radioiodinated MIBG scintigraphy in children.

Authors:  Pierre Olivier; Paula Colarinha; Jure Fettich; Sibylle Fischer; Jörgen Frökier; Francesco Giammarile; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Amy Piepsz; Ute Porn; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-26       Impact factor: 9.236

Review 3.  Pediatric oncology.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2010-08       Impact factor: 2.754

4.  Case Series on Four Treated Cases of Embryonal Rhabdomyosarcoma in Children.

Authors:  Amit Gupta; Jaseetha Sasidharan; Aditya Bhargava
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-11-26

Review 5.  Orthodontic Therapy for Paediatric Cancer Survivors: A Review.

Authors:  Sumita Mishra
Journal:  J Clin Diagn Res       Date:  2017-03-01

6.  Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia.

Authors:  Chirayu Udomsakdi-Auewarakul; Orathai Promsuwicha; Chintana Tocharoentanaphol; Chanya Munhketvit; Kovit Pattanapanyasat; Surapol Issaragrisil
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

7.  Malignant phenotype correlating with drug resistance in two human neuroblastoma cell lines.

Authors:  Y Wollman; I Shahar; M Goldstein; J Leibovici
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Congenital anomalies and genetic disorders in families of children with central nervous system tumours.

Authors:  S M Jones; P C Phillips; P T Molloy; B J Lange; M N Needle; J A Biegel
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

9.  An exploratory analysis of risk factors for childhood malignant germ-cell tumors: report from the Childrens Cancer Group (Canada, United States).

Authors:  X O Shu; M E Nesbit; J D Buckley; M D Krailo; L L Robinson
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

10.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.